Leukotrienes are a group of naturally occurring chemicals in the body that
promote inflammation in asthma and seasonal allergic rhinitis and in other diseases
in which inflammation is important (such as allergy). They are formed by cells,
released, and then bound to other cells, and it is the binding to these other
cells that stimulates the cells to promote inflammation.
Generic Singulair (Montelukast)
works in a manner similar to zafirlukast (Accolate), blocking the binding of
some leukotrienes. Unlike zafirlukast, Generic Singulair (montelukast) does not
inhibit CYP2C9 or CYP3A4, two enzymes in the liver that are important in breaking
down and eliminating many drugs. Therefore, unlike zafirlukast, Generic Singulair
(montelukast) is not expected to affect the elimination of other drugs.
The safety and effectiveness of Generic Singulair has been demonstrated in children
as young as 6 years of age. Generic Singulair was approved by the FDA in 1998.